nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—ABCG2—Riluzole—amyotrophic lateral sclerosis	0.341	1	CbGbCtD
Nilotinib—Cardiac murmur—Riluzole—amyotrophic lateral sclerosis	0.00683	0.0272	CcSEcCtD
Nilotinib—Pericarditis—Riluzole—amyotrophic lateral sclerosis	0.0049	0.0195	CcSEcCtD
Nilotinib—Furuncle—Riluzole—amyotrophic lateral sclerosis	0.00432	0.0172	CcSEcCtD
Nilotinib—EPHB3—nerve—amyotrophic lateral sclerosis	0.0042	0.0251	CbGeAlD
Nilotinib—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00414	0.0165	CcSEcCtD
Nilotinib—Micturition urgency—Riluzole—amyotrophic lateral sclerosis	0.00373	0.0148	CcSEcCtD
Nilotinib—Gastric ulcer—Riluzole—amyotrophic lateral sclerosis	0.00365	0.0145	CcSEcCtD
Nilotinib—EPHA4—nerve—amyotrophic lateral sclerosis	0.00351	0.0209	CbGeAlD
Nilotinib—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00348	0.0138	CcSEcCtD
Nilotinib—Blepharitis—Riluzole—amyotrophic lateral sclerosis	0.00344	0.0137	CcSEcCtD
Nilotinib—EPHA4—tongue—amyotrophic lateral sclerosis	0.00343	0.0204	CbGeAlD
Nilotinib—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.00337	0.0134	CcSEcCtD
Nilotinib—Oral candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00333	0.0133	CcSEcCtD
Nilotinib—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00317	0.0126	CcSEcCtD
Nilotinib—Blood creatine phosphokinase increased—Riluzole—amyotrophic lateral sclerosis	0.00308	0.0122	CcSEcCtD
Nilotinib—Haemoglobin decreased—Riluzole—amyotrophic lateral sclerosis	0.00308	0.0122	CcSEcCtD
Nilotinib—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.00305	0.0121	CcSEcCtD
Nilotinib—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.00305	0.0121	CcSEcCtD
Nilotinib—Cyanosis—Riluzole—amyotrophic lateral sclerosis	0.00299	0.0119	CcSEcCtD
Nilotinib—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.00299	0.0119	CcSEcCtD
Nilotinib—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.00299	0.0119	CcSEcCtD
Nilotinib—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00277	0.011	CcSEcCtD
Nilotinib—EPHB2—brainstem—amyotrophic lateral sclerosis	0.00274	0.0163	CbGeAlD
Nilotinib—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.00272	0.0108	CcSEcCtD
Nilotinib—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.00257	0.0102	CcSEcCtD
Nilotinib—Gamma-glutamyltransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00257	0.0102	CcSEcCtD
Nilotinib—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00256	0.0102	CcSEcCtD
Nilotinib—Breast pain—Riluzole—amyotrophic lateral sclerosis	0.00243	0.00965	CcSEcCtD
Nilotinib—MAPK14—hindbrain—amyotrophic lateral sclerosis	0.00242	0.0145	CbGeAlD
Nilotinib—MAPK8—embryo—amyotrophic lateral sclerosis	0.00239	0.0142	CbGeAlD
Nilotinib—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00236	0.00938	CcSEcCtD
Nilotinib—Ventricular extrasystoles—Riluzole—amyotrophic lateral sclerosis	0.00235	0.00932	CcSEcCtD
Nilotinib—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.00228	0.00907	CcSEcCtD
Nilotinib—Gout—Riluzole—amyotrophic lateral sclerosis	0.00227	0.00902	CcSEcCtD
Nilotinib—Leukocytosis—Riluzole—amyotrophic lateral sclerosis	0.00225	0.00896	CcSEcCtD
Nilotinib—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.00224	0.0089	CcSEcCtD
Nilotinib—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.00224	0.0089	CcSEcCtD
Nilotinib—MAPK8—brainstem—amyotrophic lateral sclerosis	0.00219	0.013	CbGeAlD
Nilotinib—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00852	CcSEcCtD
Nilotinib—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00212	0.00842	CcSEcCtD
Nilotinib—Melaena—Riluzole—amyotrophic lateral sclerosis	0.00207	0.00822	CcSEcCtD
Nilotinib—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00813	CcSEcCtD
Nilotinib—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.00202	0.00804	CcSEcCtD
Nilotinib—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00799	CcSEcCtD
Nilotinib—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.00199	0.0079	CcSEcCtD
Nilotinib—EPHB3—embryo—amyotrophic lateral sclerosis	0.00197	0.0117	CbGeAlD
Nilotinib—CA1—nerve—amyotrophic lateral sclerosis	0.00194	0.0116	CbGeAlD
Nilotinib—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00192	0.00761	CcSEcCtD
Nilotinib—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00192	0.00761	CcSEcCtD
Nilotinib—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00749	CcSEcCtD
Nilotinib—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00731	CcSEcCtD
Nilotinib—EPHB3—brainstem—amyotrophic lateral sclerosis	0.0018	0.0108	CbGeAlD
Nilotinib—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00716	CcSEcCtD
Nilotinib—MAP2K5—hindbrain—amyotrophic lateral sclerosis	0.0018	0.0107	CbGeAlD
Nilotinib—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00177	0.00703	CcSEcCtD
Nilotinib—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00177	0.00703	CcSEcCtD
Nilotinib—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.00176	0.00699	CcSEcCtD
Nilotinib—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.00175	0.00696	CcSEcCtD
Nilotinib—Deafness—Riluzole—amyotrophic lateral sclerosis	0.00172	0.00683	CcSEcCtD
Nilotinib—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00171	0.0068	CcSEcCtD
Nilotinib—CDC42BPB—medulla oblongata—amyotrophic lateral sclerosis	0.00169	0.0101	CbGeAlD
Nilotinib—EPHA4—embryo—amyotrophic lateral sclerosis	0.00164	0.0098	CbGeAlD
Nilotinib—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00164	0.0065	CcSEcCtD
Nilotinib—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.00164	0.0065	CcSEcCtD
Nilotinib—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00162	0.00645	CcSEcCtD
Nilotinib—KIT—hindbrain—amyotrophic lateral sclerosis	0.00159	0.0095	CbGeAlD
Nilotinib—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00158	0.00629	CcSEcCtD
Nilotinib—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00158	0.00626	CcSEcCtD
Nilotinib—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00154	0.00614	CcSEcCtD
Nilotinib—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.00154	0.00611	CcSEcCtD
Nilotinib—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00154	0.00611	CcSEcCtD
Nilotinib—MAPK8—medulla oblongata—amyotrophic lateral sclerosis	0.00152	0.00909	CbGeAlD
Nilotinib—CA4—nerve—amyotrophic lateral sclerosis	0.00152	0.00906	CbGeAlD
Nilotinib—MAPK14—embryo—amyotrophic lateral sclerosis	0.00152	0.00904	CbGeAlD
Nilotinib—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00151	0.00601	CcSEcCtD
Nilotinib—FGR—embryo—amyotrophic lateral sclerosis	0.00151	0.009	CbGeAlD
Nilotinib—EPHA4—brainstem—amyotrophic lateral sclerosis	0.00151	0.00898	CbGeAlD
Nilotinib—CDC42BPB—spinal cord—amyotrophic lateral sclerosis	0.0015	0.00897	CbGeAlD
Nilotinib—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00148	0.0059	CcSEcCtD
Nilotinib—EPHB2—nervous system—amyotrophic lateral sclerosis	0.00143	0.00855	CbGeAlD
Nilotinib—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00568	CcSEcCtD
Nilotinib—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00556	CcSEcCtD
Nilotinib—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00139	0.00552	CcSEcCtD
Nilotinib—MAPK14—brainstem—amyotrophic lateral sclerosis	0.00139	0.00828	CbGeAlD
Nilotinib—ABL1—hindbrain—amyotrophic lateral sclerosis	0.00139	0.00827	CbGeAlD
Nilotinib—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00138	0.0055	CcSEcCtD
Nilotinib—EPHB2—central nervous system—amyotrophic lateral sclerosis	0.00138	0.00823	CbGeAlD
Nilotinib—TEK—embryo—amyotrophic lateral sclerosis	0.00137	0.0082	CbGeAlD
Nilotinib—EPHA8—nervous system—amyotrophic lateral sclerosis	0.00137	0.0082	CbGeAlD
Nilotinib—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00541	CcSEcCtD
Nilotinib—MAPK8—spinal cord—amyotrophic lateral sclerosis	0.00136	0.00811	CbGeAlD
Nilotinib—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00539	CcSEcCtD
Nilotinib—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00539	CcSEcCtD
Nilotinib—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00532	CcSEcCtD
Nilotinib—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00528	CcSEcCtD
Nilotinib—EPHA8—central nervous system—amyotrophic lateral sclerosis	0.00132	0.00789	CbGeAlD
Nilotinib—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00518	CcSEcCtD
Nilotinib—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00129	0.00514	CcSEcCtD
Nilotinib—EPHA8—cerebellum—amyotrophic lateral sclerosis	0.00129	0.00771	CbGeAlD
Nilotinib—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00128	0.00508	CcSEcCtD
Nilotinib—MAPK11—nervous system—amyotrophic lateral sclerosis	0.00128	0.00762	CbGeAlD
Nilotinib—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00506	CcSEcCtD
Nilotinib—CDC42BPB—nervous system—amyotrophic lateral sclerosis	0.00127	0.00756	CbGeAlD
Nilotinib—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00502	CcSEcCtD
Nilotinib—PDGFRA—embryo—amyotrophic lateral sclerosis	0.00125	0.00743	CbGeAlD
Nilotinib—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00494	CcSEcCtD
Nilotinib—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00494	CcSEcCtD
Nilotinib—MAPK11—central nervous system—amyotrophic lateral sclerosis	0.00123	0.00734	CbGeAlD
Nilotinib—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00488	CcSEcCtD
Nilotinib—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00122	0.00486	CcSEcCtD
Nilotinib—CDC42BPB—central nervous system—amyotrophic lateral sclerosis	0.00122	0.00728	CbGeAlD
Nilotinib—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00482	CcSEcCtD
Nilotinib—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00481	CcSEcCtD
Nilotinib—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00478	CcSEcCtD
Nilotinib—MAPK11—cerebellum—amyotrophic lateral sclerosis	0.0012	0.00717	CbGeAlD
Nilotinib—EPHA3—nervous system—amyotrophic lateral sclerosis	0.0012	0.00716	CbGeAlD
Nilotinib—CDC42BPB—cerebellum—amyotrophic lateral sclerosis	0.00119	0.00711	CbGeAlD
Nilotinib—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00474	CcSEcCtD
Nilotinib—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00471	CcSEcCtD
Nilotinib—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00471	CcSEcCtD
Nilotinib—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00464	CcSEcCtD
Nilotinib—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00462	CcSEcCtD
Nilotinib—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00462	CcSEcCtD
Nilotinib—EPHA3—central nervous system—amyotrophic lateral sclerosis	0.00116	0.0069	CbGeAlD
Nilotinib—HCK—medulla oblongata—amyotrophic lateral sclerosis	0.00116	0.00689	CbGeAlD
Nilotinib—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00459	CcSEcCtD
Nilotinib—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00459	CcSEcCtD
Nilotinib—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00458	CcSEcCtD
Nilotinib—MAPK8—nervous system—amyotrophic lateral sclerosis	0.00115	0.00683	CbGeAlD
Nilotinib—EPHA6—nervous system—amyotrophic lateral sclerosis	0.00115	0.00683	CbGeAlD
Nilotinib—CA4—hindbrain—amyotrophic lateral sclerosis	0.00114	0.00679	CbGeAlD
Nilotinib—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00449	CcSEcCtD
Nilotinib—EPHB3—spinal cord—amyotrophic lateral sclerosis	0.00112	0.00669	CbGeAlD
Nilotinib—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00445	CcSEcCtD
Nilotinib—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00444	CcSEcCtD
Nilotinib—MAPK8—central nervous system—amyotrophic lateral sclerosis	0.0011	0.00658	CbGeAlD
Nilotinib—EPHA6—central nervous system—amyotrophic lateral sclerosis	0.0011	0.00658	CbGeAlD
Nilotinib—CSF1R—embryo—amyotrophic lateral sclerosis	0.0011	0.00654	CbGeAlD
Nilotinib—EPHB2—brain—amyotrophic lateral sclerosis	0.0011	0.00653	CbGeAlD
Nilotinib—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00108	0.0043	CcSEcCtD
Nilotinib—MAPK8—cerebellum—amyotrophic lateral sclerosis	0.00108	0.00643	CbGeAlD
Nilotinib—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00425	CcSEcCtD
Nilotinib—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00424	CcSEcCtD
Nilotinib—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00423	CcSEcCtD
Nilotinib—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00423	CcSEcCtD
Nilotinib—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00421	CcSEcCtD
Nilotinib—LYN—nervous system—amyotrophic lateral sclerosis	0.00106	0.00631	CbGeAlD
Nilotinib—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00106	0.0042	CcSEcCtD
Nilotinib—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00417	CcSEcCtD
Nilotinib—EPHA4—medulla oblongata—amyotrophic lateral sclerosis	0.00105	0.00626	CbGeAlD
Nilotinib—EPHA8—brain—amyotrophic lateral sclerosis	0.00105	0.00626	CbGeAlD
Nilotinib—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00416	CcSEcCtD
Nilotinib—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00415	CcSEcCtD
Nilotinib—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00414	CcSEcCtD
Nilotinib—HCK—spinal cord—amyotrophic lateral sclerosis	0.00103	0.00615	CbGeAlD
Nilotinib—MAP2K5—brainstem—amyotrophic lateral sclerosis	0.00103	0.00614	CbGeAlD
Nilotinib—LYN—central nervous system—amyotrophic lateral sclerosis	0.00102	0.00607	CbGeAlD
Nilotinib—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00101	0.004	CcSEcCtD
Nilotinib—KIT—embryo—amyotrophic lateral sclerosis	0.000996	0.00594	CbGeAlD
Nilotinib—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.000994	0.00395	CcSEcCtD
Nilotinib—TIE1—nervous system—amyotrophic lateral sclerosis	0.000993	0.00593	CbGeAlD
Nilotinib—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000987	0.00392	CcSEcCtD
Nilotinib—MAPK11—brain—amyotrophic lateral sclerosis	0.000976	0.00582	CbGeAlD
Nilotinib—PDGFRB—embryo—amyotrophic lateral sclerosis	0.000973	0.0058	CbGeAlD
Nilotinib—CDC42BPB—brain—amyotrophic lateral sclerosis	0.000968	0.00578	CbGeAlD
Nilotinib—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.000965	0.00384	CcSEcCtD
Nilotinib—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.000961	0.00382	CcSEcCtD
Nilotinib—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000959	0.00381	CcSEcCtD
Nilotinib—TIE1—central nervous system—amyotrophic lateral sclerosis	0.000956	0.0057	CbGeAlD
Nilotinib—Chills—Riluzole—amyotrophic lateral sclerosis	0.000955	0.00379	CcSEcCtD
Nilotinib—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00095	0.00378	CcSEcCtD
Nilotinib—EPHB3—nervous system—amyotrophic lateral sclerosis	0.000945	0.00564	CbGeAlD
Nilotinib—CA2—hindbrain—amyotrophic lateral sclerosis	0.000944	0.00563	CbGeAlD
Nilotinib—CA14—medulla oblongata—amyotrophic lateral sclerosis	0.000942	0.00562	CbGeAlD
Nilotinib—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00094	0.00374	CcSEcCtD
Nilotinib—TIE1—cerebellum—amyotrophic lateral sclerosis	0.000935	0.00558	CbGeAlD
Nilotinib—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000932	0.0037	CcSEcCtD
Nilotinib—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000926	0.00368	CcSEcCtD
Nilotinib—EPHB4—medulla oblongata—amyotrophic lateral sclerosis	0.000918	0.00548	CbGeAlD
Nilotinib—EPHA3—brain—amyotrophic lateral sclerosis	0.000918	0.00548	CbGeAlD
Nilotinib—KIT—brainstem—amyotrophic lateral sclerosis	0.000913	0.00544	CbGeAlD
Nilotinib—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.000913	0.00363	CcSEcCtD
Nilotinib—EPHB3—central nervous system—amyotrophic lateral sclerosis	0.00091	0.00543	CbGeAlD
Nilotinib—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000907	0.0036	CcSEcCtD
Nilotinib—BRAF—cerebellum—amyotrophic lateral sclerosis	0.000896	0.00535	CbGeAlD
Nilotinib—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000896	0.00356	CcSEcCtD
Nilotinib—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00089	0.00354	CcSEcCtD
Nilotinib—EPHB3—cerebellum—amyotrophic lateral sclerosis	0.000889	0.0053	CbGeAlD
Nilotinib—TEK—medulla oblongata—amyotrophic lateral sclerosis	0.000879	0.00524	CbGeAlD
Nilotinib—MAPK8—brain—amyotrophic lateral sclerosis	0.000876	0.00522	CbGeAlD
Nilotinib—EPHA6—brain—amyotrophic lateral sclerosis	0.000876	0.00522	CbGeAlD
Nilotinib—HCK—nervous system—amyotrophic lateral sclerosis	0.000868	0.00518	CbGeAlD
Nilotinib—Tremor—Riluzole—amyotrophic lateral sclerosis	0.000868	0.00345	CcSEcCtD
Nilotinib—ABL1—embryo—amyotrophic lateral sclerosis	0.000867	0.00517	CbGeAlD
Nilotinib—MAPK14—spinal cord—amyotrophic lateral sclerosis	0.000864	0.00515	CbGeAlD
Nilotinib—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000859	0.00341	CcSEcCtD
Nilotinib—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000856	0.0034	CcSEcCtD
Nilotinib—CA14—spinal cord—amyotrophic lateral sclerosis	0.00084	0.00501	CbGeAlD
Nilotinib—EPHB6—medulla oblongata—amyotrophic lateral sclerosis	0.00084	0.00501	CbGeAlD
Nilotinib—HCK—central nervous system—amyotrophic lateral sclerosis	0.000836	0.00499	CbGeAlD
Nilotinib—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000835	0.00332	CcSEcCtD
Nilotinib—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000832	0.00331	CcSEcCtD
Nilotinib—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00083	0.0033	CcSEcCtD
Nilotinib—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000829	0.00329	CcSEcCtD
Nilotinib—EPHB4—spinal cord—amyotrophic lateral sclerosis	0.000819	0.00488	CbGeAlD
Nilotinib—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.000818	0.00325	CcSEcCtD
Nilotinib—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000814	0.00323	CcSEcCtD
Nilotinib—ABL2—cerebellum—amyotrophic lateral sclerosis	0.000812	0.00484	CbGeAlD
Nilotinib—LYN—brain—amyotrophic lateral sclerosis	0.000808	0.00482	CbGeAlD
Nilotinib—Cough—Riluzole—amyotrophic lateral sclerosis	0.000808	0.00321	CcSEcCtD
Nilotinib—CA7—cerebellum—amyotrophic lateral sclerosis	0.0008	0.00477	CbGeAlD
Nilotinib—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.0008	0.00318	CcSEcCtD
Nilotinib—MAP4K1—brain—amyotrophic lateral sclerosis	0.000796	0.00475	CbGeAlD
Nilotinib—ABL1—brainstem—amyotrophic lateral sclerosis	0.000794	0.00474	CbGeAlD
Nilotinib—EPHA4—nervous system—amyotrophic lateral sclerosis	0.000789	0.00471	CbGeAlD
Nilotinib—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000788	0.00313	CcSEcCtD
Nilotinib—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000788	0.00313	CcSEcCtD
Nilotinib—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000788	0.00313	CcSEcCtD
Nilotinib—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.000786	0.00312	CcSEcCtD
Nilotinib—TEK—spinal cord—amyotrophic lateral sclerosis	0.000783	0.00467	CbGeAlD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000783	0.00311	CcSEcCtD
Nilotinib—CA3—nervous system—amyotrophic lateral sclerosis	0.000779	0.00465	CbGeAlD
Nilotinib—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000779	0.0031	CcSEcCtD
Nilotinib—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000771	0.00306	CcSEcCtD
Nilotinib—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000762	0.00303	CcSEcCtD
Nilotinib—EPHA4—central nervous system—amyotrophic lateral sclerosis	0.00076	0.00453	CbGeAlD
Nilotinib—TIE1—brain—amyotrophic lateral sclerosis	0.000759	0.00453	CbGeAlD
Nilotinib—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000756	0.003	CcSEcCtD
Nilotinib—Infection—Riluzole—amyotrophic lateral sclerosis	0.000751	0.00298	CcSEcCtD
Nilotinib—CA3—central nervous system—amyotrophic lateral sclerosis	0.00075	0.00448	CbGeAlD
Nilotinib—EPHB6—spinal cord—amyotrophic lateral sclerosis	0.000749	0.00447	CbGeAlD
Nilotinib—Shock—Riluzole—amyotrophic lateral sclerosis	0.000744	0.00295	CcSEcCtD
Nilotinib—EPHA4—cerebellum—amyotrophic lateral sclerosis	0.000743	0.00443	CbGeAlD
Nilotinib—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000741	0.00295	CcSEcCtD
Nilotinib—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00074	0.00294	CcSEcCtD
Nilotinib—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000738	0.00293	CcSEcCtD
Nilotinib—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000734	0.00292	CcSEcCtD
Nilotinib—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000731	0.0029	CcSEcCtD
Nilotinib—BRAF—brain—amyotrophic lateral sclerosis	0.000728	0.00434	CbGeAlD
Nilotinib—MAPK14—nervous system—amyotrophic lateral sclerosis	0.000728	0.00434	CbGeAlD
Nilotinib—FGR—nervous system—amyotrophic lateral sclerosis	0.000725	0.00432	CbGeAlD
Nilotinib—EPHB3—brain—amyotrophic lateral sclerosis	0.000722	0.00431	CbGeAlD
Nilotinib—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00072	0.00286	CcSEcCtD
Nilotinib—MAP2K5—medulla oblongata—amyotrophic lateral sclerosis	0.000718	0.00428	CbGeAlD
Nilotinib—PDGFRA—spinal cord—amyotrophic lateral sclerosis	0.00071	0.00423	CbGeAlD
Nilotinib—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000706	0.00281	CcSEcCtD
Nilotinib—CA9—cerebellum—amyotrophic lateral sclerosis	0.000702	0.00419	CbGeAlD
Nilotinib—CSF1R—medulla oblongata—amyotrophic lateral sclerosis	0.000701	0.00418	CbGeAlD
Nilotinib—MAPK14—central nervous system—amyotrophic lateral sclerosis	0.000701	0.00418	CbGeAlD
Nilotinib—FGR—central nervous system—amyotrophic lateral sclerosis	0.000698	0.00416	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000689	0.00274	CcSEcCtD
Nilotinib—MAPK14—cerebellum—amyotrophic lateral sclerosis	0.000685	0.00408	CbGeAlD
Nilotinib—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000684	0.00272	CcSEcCtD
Nilotinib—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000679	0.0027	CcSEcCtD
Nilotinib—EPHA2—nervous system—amyotrophic lateral sclerosis	0.000677	0.00404	CbGeAlD
Nilotinib—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000674	0.00268	CcSEcCtD
Nilotinib—CA14—cerebellum—amyotrophic lateral sclerosis	0.000666	0.00397	CbGeAlD
Nilotinib—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000665	0.00264	CcSEcCtD
Nilotinib—HCK—brain—amyotrophic lateral sclerosis	0.000664	0.00396	CbGeAlD
Nilotinib—TEK—nervous system—amyotrophic lateral sclerosis	0.00066	0.00394	CbGeAlD
Nilotinib—ABL2—brain—amyotrophic lateral sclerosis	0.000659	0.00393	CbGeAlD
Nilotinib—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000657	0.00261	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000652	0.00259	CcSEcCtD
Nilotinib—CA4—brainstem—amyotrophic lateral sclerosis	0.000652	0.00389	CbGeAlD
Nilotinib—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000652	0.00259	CcSEcCtD
Nilotinib—EPHA2—central nervous system—amyotrophic lateral sclerosis	0.000651	0.00389	CbGeAlD
Nilotinib—CA7—brain—amyotrophic lateral sclerosis	0.000649	0.00387	CbGeAlD
Nilotinib—EPHB4—cerebellum—amyotrophic lateral sclerosis	0.000649	0.00387	CbGeAlD
Nilotinib—Pain—Riluzole—amyotrophic lateral sclerosis	0.000646	0.00257	CcSEcCtD
Nilotinib—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000646	0.00257	CcSEcCtD
Nilotinib—MAP2K5—spinal cord—amyotrophic lateral sclerosis	0.00064	0.00382	CbGeAlD
Nilotinib—KIT—medulla oblongata—amyotrophic lateral sclerosis	0.000636	0.0038	CbGeAlD
Nilotinib—TEK—central nervous system—amyotrophic lateral sclerosis	0.000636	0.00379	CbGeAlD
Nilotinib—EPHB6—nervous system—amyotrophic lateral sclerosis	0.000631	0.00376	CbGeAlD
Nilotinib—CSF1R—spinal cord—amyotrophic lateral sclerosis	0.000625	0.00373	CbGeAlD
Nilotinib—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000623	0.00247	CcSEcCtD
Nilotinib—PDGFRB—medulla oblongata—amyotrophic lateral sclerosis	0.000621	0.00371	CbGeAlD
Nilotinib—TEK—cerebellum—amyotrophic lateral sclerosis	0.000621	0.00371	CbGeAlD
Nilotinib—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000618	0.00246	CcSEcCtD
Nilotinib—EPHB6—central nervous system—amyotrophic lateral sclerosis	0.000607	0.00362	CbGeAlD
Nilotinib—EPHA4—brain—amyotrophic lateral sclerosis	0.000603	0.0036	CbGeAlD
Nilotinib—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.0006	0.00239	CcSEcCtD
Nilotinib—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.000599	0.00357	CbGeAlD
Nilotinib—PDGFRA—nervous system—amyotrophic lateral sclerosis	0.000598	0.00357	CbGeAlD
Nilotinib—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000597	0.00237	CcSEcCtD
Nilotinib—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000597	0.00237	CcSEcCtD
Nilotinib—CA3—brain—amyotrophic lateral sclerosis	0.000596	0.00355	CbGeAlD
Nilotinib—EPHB6—cerebellum—amyotrophic lateral sclerosis	0.000594	0.00354	CbGeAlD
Nilotinib—CA2—embryo—amyotrophic lateral sclerosis	0.00059	0.00352	CbGeAlD
Nilotinib—PDGFRA—central nervous system—amyotrophic lateral sclerosis	0.000576	0.00343	CbGeAlD
Nilotinib—KIT—spinal cord—amyotrophic lateral sclerosis	0.000567	0.00338	CbGeAlD
Nilotinib—PDGFRA—cerebellum—amyotrophic lateral sclerosis	0.000563	0.00336	CbGeAlD
Nilotinib—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000557	0.00221	CcSEcCtD
Nilotinib—MAPK14—brain—amyotrophic lateral sclerosis	0.000556	0.00332	CbGeAlD
Nilotinib—PDGFRB—spinal cord—amyotrophic lateral sclerosis	0.000554	0.00331	CbGeAlD
Nilotinib—ABL1—medulla oblongata—amyotrophic lateral sclerosis	0.000554	0.0033	CbGeAlD
Nilotinib—FGR—brain—amyotrophic lateral sclerosis	0.000554	0.0033	CbGeAlD
Nilotinib—CA12—nervous system—amyotrophic lateral sclerosis	0.000552	0.00329	CbGeAlD
Nilotinib—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000542	0.00215	CcSEcCtD
Nilotinib—CA14—brain—amyotrophic lateral sclerosis	0.000541	0.00323	CbGeAlD
Nilotinib—CA2—brainstem—amyotrophic lateral sclerosis	0.000541	0.00323	CbGeAlD
Nilotinib—MAP2K5—nervous system—amyotrophic lateral sclerosis	0.00054	0.00322	CbGeAlD
Nilotinib—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000535	0.00212	CcSEcCtD
Nilotinib—CA12—central nervous system—amyotrophic lateral sclerosis	0.000531	0.00317	CbGeAlD
Nilotinib—EPHB4—brain—amyotrophic lateral sclerosis	0.000527	0.00314	CbGeAlD
Nilotinib—CSF1R—nervous system—amyotrophic lateral sclerosis	0.000527	0.00314	CbGeAlD
Nilotinib—MAP2K5—central nervous system—amyotrophic lateral sclerosis	0.000519	0.0031	CbGeAlD
Nilotinib—CA1—spinal cord—amyotrophic lateral sclerosis	0.000519	0.0031	CbGeAlD
Nilotinib—EPHA2—brain—amyotrophic lateral sclerosis	0.000517	0.00309	CbGeAlD
Nilotinib—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000517	0.00205	CcSEcCtD
Nilotinib—MAP2K5—cerebellum—amyotrophic lateral sclerosis	0.000508	0.00303	CbGeAlD
Nilotinib—CSF1R—central nervous system—amyotrophic lateral sclerosis	0.000507	0.00302	CbGeAlD
Nilotinib—TEK—brain—amyotrophic lateral sclerosis	0.000505	0.00301	CbGeAlD
Nilotinib—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.0005	0.00199	CcSEcCtD
Nilotinib—CSF1R—cerebellum—amyotrophic lateral sclerosis	0.000495	0.00296	CbGeAlD
Nilotinib—ABL1—spinal cord—amyotrophic lateral sclerosis	0.000494	0.00295	CbGeAlD
Nilotinib—EPHB6—brain—amyotrophic lateral sclerosis	0.000482	0.00288	CbGeAlD
Nilotinib—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000481	0.00191	CcSEcCtD
Nilotinib—KIT—nervous system—amyotrophic lateral sclerosis	0.000478	0.00285	CbGeAlD
Nilotinib—Rash—Riluzole—amyotrophic lateral sclerosis	0.000477	0.00189	CcSEcCtD
Nilotinib—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000476	0.00189	CcSEcCtD
Nilotinib—Headache—Riluzole—amyotrophic lateral sclerosis	0.000473	0.00188	CcSEcCtD
Nilotinib—PDGFRB—nervous system—amyotrophic lateral sclerosis	0.000467	0.00279	CbGeAlD
Nilotinib—KIT—central nervous system—amyotrophic lateral sclerosis	0.00046	0.00275	CbGeAlD
Nilotinib—PDGFRA—brain—amyotrophic lateral sclerosis	0.000457	0.00273	CbGeAlD
Nilotinib—CA4—medulla oblongata—amyotrophic lateral sclerosis	0.000455	0.00271	CbGeAlD
Nilotinib—KIT—cerebellum—amyotrophic lateral sclerosis	0.00045	0.00268	CbGeAlD
Nilotinib—PDGFRB—central nervous system—amyotrophic lateral sclerosis	0.00045	0.00268	CbGeAlD
Nilotinib—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000449	0.00178	CcSEcCtD
Nilotinib—PDGFRB—cerebellum—amyotrophic lateral sclerosis	0.000439	0.00262	CbGeAlD
Nilotinib—CA1—nervous system—amyotrophic lateral sclerosis	0.000437	0.00261	CbGeAlD
Nilotinib—CA12—brain—amyotrophic lateral sclerosis	0.000422	0.00252	CbGeAlD
Nilotinib—CA1—central nervous system—amyotrophic lateral sclerosis	0.000421	0.00251	CbGeAlD
Nilotinib—ABL1—nervous system—amyotrophic lateral sclerosis	0.000416	0.00248	CbGeAlD
Nilotinib—MAP2K5—brain—amyotrophic lateral sclerosis	0.000412	0.00246	CbGeAlD
Nilotinib—CA4—spinal cord—amyotrophic lateral sclerosis	0.000406	0.00242	CbGeAlD
Nilotinib—CSF1R—brain—amyotrophic lateral sclerosis	0.000402	0.0024	CbGeAlD
Nilotinib—ABL1—central nervous system—amyotrophic lateral sclerosis	0.000401	0.00239	CbGeAlD
Nilotinib—ABL1—cerebellum—amyotrophic lateral sclerosis	0.000392	0.00234	CbGeAlD
Nilotinib—CA2—medulla oblongata—amyotrophic lateral sclerosis	0.000377	0.00225	CbGeAlD
Nilotinib—KIT—brain—amyotrophic lateral sclerosis	0.000365	0.00218	CbGeAlD
Nilotinib—PDGFRB—brain—amyotrophic lateral sclerosis	0.000357	0.00213	CbGeAlD
Nilotinib—ABCG2—medulla oblongata—amyotrophic lateral sclerosis	0.000349	0.00208	CbGeAlD
Nilotinib—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000343	0.00205	CbGeAlD
Nilotinib—CA4—nervous system—amyotrophic lateral sclerosis	0.000342	0.00204	CbGeAlD
Nilotinib—CA2—spinal cord—amyotrophic lateral sclerosis	0.000336	0.00201	CbGeAlD
Nilotinib—CA1—brain—amyotrophic lateral sclerosis	0.000334	0.00199	CbGeAlD
Nilotinib—CA4—central nervous system—amyotrophic lateral sclerosis	0.000329	0.00196	CbGeAlD
Nilotinib—CA4—cerebellum—amyotrophic lateral sclerosis	0.000322	0.00192	CbGeAlD
Nilotinib—ABL1—brain—amyotrophic lateral sclerosis	0.000318	0.0019	CbGeAlD
Nilotinib—ABCG2—spinal cord—amyotrophic lateral sclerosis	0.000311	0.00186	CbGeAlD
Nilotinib—CA2—nervous system—amyotrophic lateral sclerosis	0.000283	0.00169	CbGeAlD
Nilotinib—CA2—central nervous system—amyotrophic lateral sclerosis	0.000273	0.00163	CbGeAlD
Nilotinib—ABCB1—embryo—amyotrophic lateral sclerosis	0.00027	0.00161	CbGeAlD
Nilotinib—CA2—cerebellum—amyotrophic lateral sclerosis	0.000267	0.00159	CbGeAlD
Nilotinib—CA4—brain—amyotrophic lateral sclerosis	0.000261	0.00156	CbGeAlD
Nilotinib—ABCG2—cerebellum—amyotrophic lateral sclerosis	0.000247	0.00147	CbGeAlD
Nilotinib—CYP2B6—nervous system—amyotrophic lateral sclerosis	0.000242	0.00144	CbGeAlD
Nilotinib—CYP2B6—central nervous system—amyotrophic lateral sclerosis	0.000233	0.00139	CbGeAlD
Nilotinib—CA2—brain—amyotrophic lateral sclerosis	0.000217	0.00129	CbGeAlD
Nilotinib—CYP2C8—brain—amyotrophic lateral sclerosis	0.000206	0.00123	CbGeAlD
Nilotinib—ABCG2—brain—amyotrophic lateral sclerosis	0.000201	0.0012	CbGeAlD
Nilotinib—CYP2B6—brain—amyotrophic lateral sclerosis	0.000185	0.0011	CbGeAlD
Nilotinib—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000183	0.00109	CbGeAlD
Nilotinib—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.00018	0.00107	CbGeAlD
Nilotinib—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000176	0.00105	CbGeAlD
Nilotinib—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000173	0.00103	CbGeAlD
Nilotinib—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000172	0.00103	CbGeAlD
Nilotinib—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000169	0.00101	CbGeAlD
Nilotinib—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000154	0.000916	CbGeAlD
Nilotinib—CYP2D6—brain—amyotrophic lateral sclerosis	0.000138	0.00082	CbGeAlD
Nilotinib—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000129	0.000772	CbGeAlD
Nilotinib—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000125	0.000743	CbGeAlD
Nilotinib—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000122	0.000726	CbGeAlD
Nilotinib—ABCB1—brain—amyotrophic lateral sclerosis	9.89e-05	0.00059	CbGeAlD
Nilotinib—CA2—Metabolism—APOE—amyotrophic lateral sclerosis	1.96e-05	8.18e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.96e-05	8.17e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CASP9—amyotrophic lateral sclerosis	1.95e-05	8.13e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—ERBB4—amyotrophic lateral sclerosis	1.95e-05	8.12e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—C3—amyotrophic lateral sclerosis	1.95e-05	8.1e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CASP9—amyotrophic lateral sclerosis	1.94e-05	8.09e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	1.94e-05	8.07e-05	CbGpPWpGaD
Nilotinib—CA7—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.9e-05	7.92e-05	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.9e-05	7.91e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.9e-05	7.91e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—SQSTM1—amyotrophic lateral sclerosis	1.89e-05	7.87e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—APOE—amyotrophic lateral sclerosis	1.88e-05	7.85e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD40LG—amyotrophic lateral sclerosis	1.88e-05	7.82e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.86e-05	7.73e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—ERBB4—amyotrophic lateral sclerosis	1.84e-05	7.68e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.84e-05	7.66e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GSR—amyotrophic lateral sclerosis	1.84e-05	7.66e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	1.83e-05	7.61e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	1.81e-05	7.54e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.81e-05	7.52e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—ERBB4—amyotrophic lateral sclerosis	1.8e-05	7.5e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.8e-05	7.49e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.79e-05	7.44e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.78e-05	7.43e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.78e-05	7.4e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—ATF1—amyotrophic lateral sclerosis	1.77e-05	7.38e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.77e-05	7.36e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—ERBB4—amyotrophic lateral sclerosis	1.76e-05	7.34e-05	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—TP53—amyotrophic lateral sclerosis	1.76e-05	7.34e-05	CbGpPWpGaD
Nilotinib—CA12—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.76e-05	7.33e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—IGF1—amyotrophic lateral sclerosis	1.76e-05	7.33e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—ERBB4—amyotrophic lateral sclerosis	1.75e-05	7.31e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—C3—amyotrophic lateral sclerosis	1.75e-05	7.3e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.75e-05	7.29e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.7e-05	7.07e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD40LG—amyotrophic lateral sclerosis	1.69e-05	7.05e-05	CbGpPWpGaD
Nilotinib—MAPK14—Cellular responses to stress—TP53—amyotrophic lateral sclerosis	1.69e-05	7.04e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.69e-05	7.04e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CASP9—amyotrophic lateral sclerosis	1.69e-05	7.03e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	1.69e-05	7.02e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.67e-05	6.97e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—ERBB4—amyotrophic lateral sclerosis	1.67e-05	6.96e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	1.67e-05	6.94e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—ERBB4—amyotrophic lateral sclerosis	1.66e-05	6.92e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—C3—amyotrophic lateral sclerosis	1.66e-05	6.91e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD40LG—amyotrophic lateral sclerosis	1.66e-05	6.9e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—APOE—amyotrophic lateral sclerosis	1.66e-05	6.9e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—APOE—amyotrophic lateral sclerosis	1.66e-05	6.9e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	1.65e-05	6.88e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	1.65e-05	6.88e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD40LG—amyotrophic lateral sclerosis	1.65e-05	6.87e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.59e-05	6.64e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.59e-05	6.63e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—PTGS2—amyotrophic lateral sclerosis	1.59e-05	6.61e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.59e-05	6.6e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.58e-05	6.6e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.58e-05	6.57e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD40LG—amyotrophic lateral sclerosis	1.57e-05	6.54e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CASP9—amyotrophic lateral sclerosis	1.56e-05	6.49e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	1.56e-05	6.48e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	1.55e-05	6.45e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.52e-05	6.34e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.51e-05	6.3e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	1.51e-05	6.29e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.51e-05	6.29e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.51e-05	6.29e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.51e-05	6.29e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—APOE—amyotrophic lateral sclerosis	1.51e-05	6.28e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.5e-05	6.25e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.5e-05	6.24e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—C3—amyotrophic lateral sclerosis	1.5e-05	6.23e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.49e-05	6.21e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	1.47e-05	6.12e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.47e-05	6.12e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—C3—amyotrophic lateral sclerosis	1.46e-05	6.1e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—C3—amyotrophic lateral sclerosis	1.46e-05	6.07e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—ERBB4—amyotrophic lateral sclerosis	1.44e-05	6.02e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.43e-05	5.96e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.43e-05	5.95e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—APOE—amyotrophic lateral sclerosis	1.43e-05	5.94e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.42e-05	5.93e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.42e-05	5.93e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.42e-05	5.9e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.41e-05	5.88e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.41e-05	5.87e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.4e-05	5.85e-05	CbGpPWpGaD
Nilotinib—CA4—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.4e-05	5.85e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.4e-05	5.84e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.4e-05	5.82e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.4e-05	5.82e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.4e-05	5.82e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—C3—amyotrophic lateral sclerosis	1.39e-05	5.78e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	1.38e-05	5.77e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	1.37e-05	5.72e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.36e-05	5.68e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.36e-05	5.66e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD40LG—amyotrophic lateral sclerosis	1.36e-05	5.66e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	1.36e-05	5.65e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.36e-05	5.65e-05	CbGpPWpGaD
Nilotinib—CA2—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.35e-05	5.61e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—ERBB4—amyotrophic lateral sclerosis	1.33e-05	5.55e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.33e-05	5.54e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.33e-05	5.54e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.32e-05	5.52e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	1.32e-05	5.5e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	1.31e-05	5.47e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.3e-05	5.43e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.29e-05	5.38e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.29e-05	5.38e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—APOE—amyotrophic lateral sclerosis	1.29e-05	5.35e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.28e-05	5.34e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	1.28e-05	5.32e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	1.28e-05	5.32e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	1.27e-05	5.28e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.26e-05	5.26e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.26e-05	5.24e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.25e-05	5.19e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.22e-05	5.09e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.21e-05	5.06e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.21e-05	5.06e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—C3—amyotrophic lateral sclerosis	1.2e-05	5e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.2e-05	4.99e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.19e-05	4.97e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.17e-05	4.88e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.17e-05	4.86e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.16e-05	4.85e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.16e-05	4.83e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.15e-05	4.81e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.15e-05	4.8e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.15e-05	4.79e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.15e-05	4.77e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.14e-05	4.75e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—PTGS2—amyotrophic lateral sclerosis	1.13e-05	4.73e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.13e-05	4.73e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.13e-05	4.72e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.11e-05	4.64e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.11e-05	4.61e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.09e-05	4.56e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.09e-05	4.54e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.08e-05	4.5e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.07e-05	4.47e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.07e-05	4.46e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TP53—amyotrophic lateral sclerosis	1.06e-05	4.42e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.06e-05	4.4e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TP53—amyotrophic lateral sclerosis	1.06e-05	4.4e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.05e-05	4.37e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	1.04e-05	4.33e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—PTGS2—amyotrophic lateral sclerosis	1.03e-05	4.3e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—APOE—amyotrophic lateral sclerosis	1.03e-05	4.3e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.02e-05	4.24e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.02e-05	4.23e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TP53—amyotrophic lateral sclerosis	1.01e-05	4.19e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9.99e-06	4.16e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	9.92e-06	4.13e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—APOE—amyotrophic lateral sclerosis	9.86e-06	4.11e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PTGS2—amyotrophic lateral sclerosis	9.78e-06	4.07e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.67e-06	4.03e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—C3—amyotrophic lateral sclerosis	9.67e-06	4.03e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.58e-06	3.99e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	9.49e-06	3.95e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—C3—amyotrophic lateral sclerosis	9.47e-06	3.94e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.35e-06	3.89e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	9.34e-06	3.89e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	9.05e-06	3.77e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9e-06	3.75e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—C3—amyotrophic lateral sclerosis	8.98e-06	3.74e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.89e-06	3.7e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.83e-06	3.68e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—APOE—amyotrophic lateral sclerosis	8.81e-06	3.67e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PTGS2—amyotrophic lateral sclerosis	8.81e-06	3.67e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	8.78e-06	3.66e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.72e-06	3.63e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—amyotrophic lateral sclerosis	8.69e-06	3.62e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.4e-06	3.5e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—APOE—amyotrophic lateral sclerosis	8.37e-06	3.49e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—APOE—amyotrophic lateral sclerosis	8.36e-06	3.48e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	8.35e-06	3.48e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.26e-06	3.44e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.11e-06	3.38e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	7.99e-06	3.33e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.93e-06	3.3e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—C3—amyotrophic lateral sclerosis	7.76e-06	3.23e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.54e-06	3.14e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.46e-06	3.11e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.45e-06	3.1e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	7.44e-06	3.1e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.38e-06	3.07e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	7.28e-06	3.03e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—APOE—amyotrophic lateral sclerosis	7.22e-06	3.01e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTGS2—amyotrophic lateral sclerosis	7.07e-06	2.94e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.04e-06	2.93e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.97e-06	2.9e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.9e-06	2.88e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.87e-06	2.86e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	6.86e-06	2.86e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.76e-06	2.81e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.71e-06	2.8e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	6.5e-06	2.71e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.36e-06	2.65e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.35e-06	2.64e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.32e-06	2.63e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.31e-06	2.63e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.26e-06	2.61e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—APOE—amyotrophic lateral sclerosis	6.14e-06	2.56e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.01e-06	2.5e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.99e-06	2.5e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.99e-06	2.49e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.97e-06	2.49e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.74e-06	2.39e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.73e-06	2.38e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.7e-06	2.37e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.7e-06	2.37e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.64e-06	2.35e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.61e-06	2.33e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.59e-06	2.33e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.5e-06	2.29e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.41e-06	2.25e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.39e-06	2.25e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.31e-06	2.21e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.3e-06	2.21e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	5.19e-06	2.16e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.18e-06	2.16e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.14e-06	2.14e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.02e-06	2.09e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.86e-06	2.02e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.77e-06	1.99e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.76e-06	1.98e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.73e-06	1.97e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.6e-06	1.91e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	4.53e-06	1.88e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.51e-06	1.88e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.34e-06	1.81e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.31e-06	1.79e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	4.26e-06	1.78e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	4.23e-06	1.76e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.2e-06	1.75e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.08e-06	1.7e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.9e-06	1.62e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.69e-06	1.54e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.67e-06	1.53e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.59e-06	1.5e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.56e-06	1.48e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.41e-06	1.42e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.39e-06	1.41e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.1e-06	1.29e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.95e-06	1.23e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.92e-06	1.22e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.9e-06	1.21e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	2.79e-06	1.16e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.91e-06	7.96e-06	CbGpPWpGaD
